Vaxxinity is a biotechnology company. Co.'s pipeline consists of five chronic disease product candidates including UB-311, which targets toxic forms of aggregated Ab in the brain to fight Alzheimer's Disease; UB-312, which targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's Disease and other synucleinopathies; an anti-tau product candidate that has the potential to address various neurodegenerative conditions; UB-313, which targets Calcitonin Gene-Related Peptide to fight migraines; and Anti-PCSK9, which targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events. The VAXX average annual return since 2021 is shown above.
The Average Annual Return on the VAXX average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether VAXX average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the VAXX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|